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Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES), BiolimusA9 (BES), EPC 
capture (ECS) and Everolimus-eluting stent (EES) on the outcome of patients with chronic total occlusion (CTO). 
Methods: A prospective analysis of 1148 patients with 1253 CTOs (396 SES, 526 PES, 177 ZES, 70 BES, 41 ECS, 43 EES) in six high volume Asian 
centers after successful recanalization of CTO was performed. The study endpoints were 30 days and 9 months major adverse cardiac events (MACE), 
9 months angiographic restenosis and target lesion revascularization (TLR). 
Results: See table for clinical results.  
Conclusion: The use of drug-eluting stents in patients with CTO was safe with low acute complication. Patients treated with SES, BES and EES 
showed lesser rate of restenosis compared with other drug-eluting stents. 
SES PES ZES BES ECS EES
Number of patients/lesions 365/396 482/526 154/177 66/70 39/41 42/43
LAD/LCX/RCA (%) 54/26/20 52/22/26 50/22/28 46/23/31 52/24/24 58/16/26
Procedural success (%) 100 100 100 100 100 100
MACE at 30 days (%) 0 0.4 0.6 0 0 0
Proximal reference diameter (mean: mm) 2.86 2.80 2.83 2.88 2.90 2.88
Minimum lumen diameter at post (mean: mm) 2.65 2.54 2.59 2.79 2.60 2.68
Minimum lumen diameter at 9 mo. (mean: mm) 2.55 2.33 2.09 2.67 2.34 2.59
Restenosis rate at 9 months (%) 4.0* 6.7 12.3 4.5* 12.8 4.8*
TLR at 9 months (%) 3.6* 6.7 10.4 4.5* 10.3 2.4*
MACE at 9 months (%) 3.6* 6.7 10.4 4.5* 10.3 2.4*
*p<0.05 vs. ZES, ECS
